EGFR and non-small cell lung carcinoma: In particular, third-generation TKIs transformed the standard frontline treatment for advanced EGFR-mutant NSCLC as the preferred first-line treatment in clinical guidelines [7], owing to better efficacy and fewer side effects [8].